Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) EPS (Weighted Average and Diluted): 2019-2024

Historic EPS (Weighted Average and Diluted) for Akebia Therapeutics (AKBA) over the last 6 years, with Dec 2024 value amounting to -$0.33.

  • Akebia Therapeutics' EPS (Weighted Average and Diluted) rose 101.97% to $0.00 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.08, marking a year-over-year increase of 65.98%. This contributed to the annual value of -$0.33 for FY2024, which is 17.86% down from last year.
  • Latest data reveals that Akebia Therapeutics reported EPS (Weighted Average and Diluted) of -$0.33 as of FY2024, which was down 17.86% from -$0.28 recorded in FY2023.
  • Akebia Therapeutics' EPS (Weighted Average and Diluted)'s 5-year high stood at -$0.28 during FY2023, with a 5-year trough of -$2.78 in FY2020.
  • For the 3-year period, Akebia Therapeutics' EPS (Weighted Average and Diluted) averaged around -$0.38, with its median value being -$0.33 (2024).
  • In the last 5 years, Akebia Therapeutics' EPS (Weighted Average and Diluted) soared by 69.41% in 2022 and then dropped by 17.86% in 2024.
  • Over the past 5 years, Akebia Therapeutics' EPS (Weighted Average and Diluted) (MRY) stood at -$2.78 in 2020, then surged by 38.85% to -$1.70 in 2021, then soared by 69.41% to -$0.52 in 2022, then skyrocketed by 46.15% to -$0.28 in 2023, then fell by 17.86% to -$0.33 in 2024.
  • Its last three reported values are -$0.33 in FY2024, -$0.28 for FY2023, and -$0.52 during FY2022.